KindlyMD Announces Closing of $6.8 Million Initial Public Offering
KindlyMD Announces Closing of $6.8 Million Initial Public Offering
SALT LAKE CITY, UT / ACCESSWIRE / June 3, 2024 / KindlyMD, Inc. (NASDAQ:KDLY)(NASDAQ:KDLYW) ("KindlyMD" or the "Company"), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, including the recommendation of medical cannabis in patient treatment plans in compliance with a legalized state medical cannabis regulatory scheme, today announced the closing of its previously announced initial public offering of 1,240,910 units (each, a "Unit," collectively, the "Units") at a price of $5.50 per Unit for a total of approximately $6.8 million of gross proceeds to the Company, prior to deducting underwriting discounts and offering expenses. Each Unit is comprised of one share of the Company's common stock with $0.001 par value per share ("Common Stock"), one tradeable warrant (each, a "Tradeable Warrant," collectively, the "Tradeable Warrants") to purchase one share of Common Stock at an exercise price of $6.33 per share, and one non-tradeable warrant (each, a "Non-tradeable Warrant," collectively, the "Non-tradeable Warrants") to purchase one-half of one share of Common Stock at an exercise price of $6.33 per share. The units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of Common Stock and the Warrants comprising the Units are immediately separable upon issuance and will be used separately in this offering. Each Warrant offered as a part of this offering is immediately exercisable upon issuance and will expire five years from the date of issuance.
KindlyMD,Inc.(納斯達克:KDLY)(納斯達克:KDLYW)是一家以患者爲第一的醫療保健和醫療保健數據公司,獨特地將傳統的初級保健和疼痛管理策略與整合的行爲和替代療法相結合,包括在合法化的州醫用大麻監管計劃的框架內推薦醫用大麻在患者治療計劃中,今天宣佈以每個單位5.50美元的價格,發行了1,240,910個單位(每個單位一個“Unit”,合計“Units”)的首次公開發行,爲公司帶來了大約680萬美元的總收益,在扣除承銷折扣和發行費用之前。每個單位由一股公司的普通股組成,每股面值0.001美元(“普通股”),一張可交易的認股權證(每股一張,集體爲“可交易權證”),行使價格爲每股6.33美元,一張不可交易的認股權證(每股一半,集體爲“不可交易權證”),行使價格爲每股6.33美元。該單位沒有獨立的權利,也不會被作爲獨立證券證明或發放。組成單位的普通股和權證在發行後可以立即分離,並將單獨在本次發行中使用。本次發行中提供的每張認股權證在發行後可以立即行使,並將於發行後五年到期。
The shares and Tradeable Warrants began trading on the Nasdaq Capital Market on May 31, 2024, under the symbols "KDLY" and "KDLYW," respectively.
股份和可交易權證於2024年5月31日在納斯達克資本市場上交易,股票代號爲“KDLY”,交易權證代號爲“KDLYW”。
In addition, KindlyMD has granted the underwriters a 45-day option to purchase, at the public offering price, up to an additional 186,136 shares of Common Stock and/or 186,136 Tradeable Warrants, and/or 186,136 Non-Tradeable Warrants, or any combination thereof, at the public offering price per share of Common Stock and per Warrant, respectively, less, in each case, underwriting discounts and commissions, on the same terms as set forth in this prospectus, solely to cover over-allotments, if any.
此外,KindlyMD授予承銷商有權在45天內購買額外的18萬6136股普通股和/或18萬6136張可交易權證和/或18萬6136張不可交易權證,或它們的任何組合,每股普通股和每張認股權證,按發行價公開發行,扣除承銷折扣和佣金,僅爲了彌補超額配售。
WallachBeth Capital LLC is the Sole Bookrunner for the offering.
WallachBeth Capital LLC是本次發行的唯一承銷商。
The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from WallachBeth Capital, LLC, via email: cap-mkts@wallachbeth.com, or by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the Securities and Exchange Commission's ("SEC") website at www.sec.gov.
本次發行僅作爲一份資料的形式。與此次發行有關的最終發售說明書副本可以從WallachBeth Capital,LLC得到,通過電子郵件:cap-mkts@wallachbeth.com,或通過電話+1(646)237-8585或通過標準郵件發送到WallachBeth Capital LLC,Attn:Capital Markets,185 Hudson St.,Suite 1410,Jersey City,NJ 07311,美國。此外,當這份發行與發售有關的最終招股說明書可獲得時,可以從證券交易委員會(“SEC”)的網站www.sec.gov獲得。
A registration statement on Form S-1, as amended (File No. 333-274606), relating to these securities was filed with the SEC and was declared effective on May 13, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
本新聞稿不構成出售或要約出售這些證券的要約,也不在任何州或司法管轄區出售這些證券構成任何違反任何這些州或司法管轄區的證券法律的行爲。
About KindlyMD
關於KindlyMD
KindlyMD is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
KindlyMD是一家以患者爲中心的醫療保健和醫療保健數據公司,獨特地將傳統的初級保健和疼痛管理策略與整合的行爲和替代療法相結合,以提供全面的護理,減少美國的阿片類藥物使用的成癮和依賴性。 KindlyMD目前運營着四個中心,包括猶他州最大的替代疼痛治療中心。憑藉其專業門診服務,包括KindlyMD醫療保健提供者推薦使用醫用大麻進行整體疼痛管理,KindlyMD正在提供更好的患者健康結果。
For more information, please visit .
有關更多信息,請訪問。
Forward-Looking Statements
前瞻性聲明
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" in KindlyMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. KindlyMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
本新聞稿包含某些基於目前預期並涉及某些風險和不確定性的前瞻性聲明,這些前瞻性聲明是根據美國1995年私人證券訴訟改革法而制定的,用諸如“應該”“可能”“打算”“預計”“認爲”“估計”“project”“預測”“期望”“計劃”和“建議”的詞語進行識別。這些前瞻性聲明並非未來績效的保證,並且要承受風險,不確定性和其他因素,其中部分超出我們的控制範圍並難以預測,這些因素可能會導致實際結果與前瞻性聲明中的表達或預測不一致。我們建議您仔細審查和考慮任何警示性聲明和其他披露,包括納入的“風險因素”下所述的聲明,並評估可能影響我們的業務,財務狀況和結果的所有因素。在KindlyMD,Inc.的2022財年報表10-K下某些前瞻性聲明中,不要承擔任何更新前瞻性聲明的義務,除非法律規定。出現在我們網站和社交媒體平台(包括但不限於Instagram和Facebook)上的信息不屬於本新聞稿。
Investor Relations Contact:
投資者關係聯繫人:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
kindlymd@kcsa.com
Valter Pinto, 董事總經理
KCSA戰略傳播
(212) 896-1254
kindlymd@kcsa.com
SOURCE: KindlyMD, Inc
來源:KindlyMD,Inc。